Inactive Instrument

Other languages ImmunoGen, Inc.

Equities

IMGN

US45253H1014

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

AbbVie CEO to Retire; COO Robert Michael Named Successor	Feb. 20
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	Feb. 13
Top Stories at Midday: Bezos Sells Nearly 12 Million Amazon Shares; Diamondback's $26 Billion Endeavor Energy Deal; Citigroup's Risk Management Procedures Rebuked; AbbVie Buys ImmunoGen	Feb. 12
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	Feb. 12
Diamondback Energy : Abbvie, Diamondback Energy, Gilead...les valeurs à suivre aujourd'hui à Wall Street	Feb. 12
Abbvie : abaisse ses perspectives après le rachat d'Immunogen	Feb. 12
AbbVie : acquisition d'ImmunoGen finalisée	Feb. 12
Immunogen, Inc. Announces Board Changes	Feb. 12
AbbVie Inc. completed the acquisition of ImmunoGen, Inc. from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc., State Street Corporation, The Vanguard Group, Inc. and others.	Feb. 11
ImmunoGen Insider Sold Shares Worth $352,391, According to a Recent SEC Filing	Feb. 07
ImmunoGen Insider Sold Shares Worth $588,733, According to a Recent SEC Filing	Feb. 07
Omzetdaling Abbvie valt mee	Feb. 02
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	Feb. 02
HBM bleibt nach neun Monaten in den roten Zahlen	Jan. 22
HBM confirme sa lourde perte sur les neuf premiers mois de 2023/24	Jan. 22
Immunogen Insider Sold Shares Worth $5,562,450, According to a Recent SEC Filing	Jan. 19
Drugmakers kick off industry conference with two cancer deals	Jan. 08
J&J to buy cancer therapy developer Ambrx for $2 bln	Jan. 08
HBM s'attend à une lourde perte sur neuf mois	Jan. 04
HBM erwartet nach neun Monaten Verlust von 158 Mio Franken	Jan. 03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ImmunoGen, Inc.

Equities

IMGN

US45253H1014

Other languages

Filters